Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for PNALD
NCT00910104Phase 3Completed
- Start
- Aug 2006
- Primary completion
- Jan 2019
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in Parenteral Nutrition Associated Liver Disease (PNALD). Primary endpoint: Reversal of Cholestasis. Started Aug 2006; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD)
Beyond the preview
Go deeper on NCT00910104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00910104.